Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.
This review shows how tumor antigen cross-presentation is affected by the major therapeutic modalities including chemotherapy, radiotherapy, and surgery. We argue that this process could affect the way that a tumor works as its own cellular vaccine, and that it is differentially modulated by the choice of treatment.
van der Most
Robbert G
RG
School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Perth 6009, Australia.
Currie
Andrew
A
Robinson
Bruce W S
BW
Lake
Richard A
RA
D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D003131:Combined Modality Therapy; D045142:Cross-Priming / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D019496:Cancer Vaccines